Biotech Dodo

🦤 Psssst…this week’s edition is filled with intrigue: from high-level exits to secret funding deals. It’s all hush-hush for now, but we’re here to lift the lid👇 👣 BenevolentAI CEO steps down as founders make a comeback (Phil Taylor) 🤫 Secretive Treeline Biosciences discloses $421M financing in filing (Nick Paul Taylor) 👻 Another Roche MAGE-A4 trial withdrawn (Liam Casey) 💰Ontario invests $146M in hopes of becoming life sciences hub (Dr. Sushama Chaphalkar) 🔬Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease (Kyle LaHucik, Andrew Dunn) Tune into… 🎧 Tips for Effective Communication in Biotech with Carolyn Scofield, MPS 🎧 Replacing Cells, Restoring Sight with Brian Culley 🎧 The future of gene therapy with Michael Parini Apply to… 📎 Upstream Bioprocess Lead, NanoSyrinx 📎 Senior Scientist in Bio-Physics, Domainex 📎 Scientist II/III Process Development, Oxford Biomedica Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #19 out now: https://lnkd.in/ewqdH36A #biotechdodo #biotech #pharma #digitalhealth #healthtech

🦤 This week, we have drama alongside some big power plays... Brazil brings rare gene therapies to the public, Pfizer's former execs flip-flop, researchers zoom in on bacterial ion targets, scientists create viral 'decoys', and efforts are underway to ensure more diverse genome datasets👇 🇧🇷 GEMMABio secures $100M partnership with health ministry to bring rare disease gene therapies to Brazil (Darren Incorvaia) 🩴 Former Pfizer CEO and CFO flip on activist and say they now support company (Drew Armstrong & Max Bayer) 🩻 X-ray scattering technique pinpoints new targets for antibiotic drug development (University of London) 🪤 Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus (VIB) ⚖️ Diverse genomes make medicine more equitable (Sachin Rawat) Tune into… 🎧 From Bench to podcast with Chloe Fishman and from Gladstone Institutes 🎧 First Reactions - Nobel Prize Conversations with Gary Ruvkun from Harvard University 🎧 World-first ovarian cancer vaccine with Professor Ahmed Ashour Ahmed from MRC Weatherall Institute of Molecular Medicine Apply to… 📎 Research Scientist, Isomorphic Labs 📎 Cell Therapy Engagement Manager, AstraZeneca 📎 Scientific Junior Group Leaders, Roche Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #18 out now: https://lnkd.in/gVDmy7EP #BiotechDodo #Biotech #Pharma #DigitalHealth #HealthTech

🦤 This week, we have drama alongside some big power plays... Brazil brings rare gene therapies to the public, Pfizer's former execs flip-flop, researchers zoom in on bacterial ion targets, scientists create viral 'decoys', and efforts are underway to ensure more diverse genome datasets👇 🇧🇷 GEMMABio secures $100M partnership with health ministry to bring rare disease gene therapies to Brazil (Darren Incorvaia) 🩴 Former Pfizer CEO and CFO flip on activist and say they now support company (Drew Armstrong & Max Bayer) 🩻 X-ray scattering technique pinpoints new targets for antibiotic drug development (University of London) 🪤 Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus (VIB) ⚖️ Diverse genomes make medicine more equitable (Sachin Rawat) Tune into… 🎧 From Bench to podcast with Chloe Fishman and from Gladstone Institutes 🎧 First Reactions - Nobel Prize Conversations with Gary Ruvkun from Harvard University 🎧 World-first ovarian cancer vaccine with Professor Ahmed Ashour Ahmed from MRC Weatherall Institute of Molecular Medicine Apply to… 📎 Research Scientist, Isomorphic Labs 📎 Cell Therapy Engagement Manager, AstraZeneca 📎 Scientific Junior Group Leaders, Roche Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #18 out now: https://lnkd.in/gVDmy7EP #BiotechDodo #Biotech #Pharma #DigitalHealth #HealthTech

🦤 This week, we have some big brain thinking in biotech (don’t we always?!) 2seventy bio’s plan to breakeven, Eli Lilly investing in a new drug manufacturing hub, cracking the code for off-the-shelf CAR-T therapy, and a neural map of the small fry fruit fly. Plus, let’s give a standing ovation to the Nobel Prize winners  – a very exciting result for biotech innovators!  👏 🇨🇳 World-first therapy using donor cells sends autoimmune diseases into remission (Smriti Felicitas Mallapaty) 🧫 As 2seventy nears breakeven, CEO Chip Baird explains how the team survived (Annalee Armstrong) 🏗️ Lilly shells out $4.5 billion for new drug development plant (Madison Muller) 🧠 Why a map of a fruit fly’s brain has neuroscientists ‘blown away’ (Anil Oza) 🏆 The Nobel Prizes 2024 (The Nobel Prize) Tune into… 🎧 What are vaccines? With Eliot Forster and Antonin de Fougerolles, former CEO of Evox Therapeutics 🎧 Automating bioprocessing to speed up workflows with Martin Tromp Permin, Co-Founder of Invert 🎧 From microbiome to macrobiome with Braden Tierney, Co-Founder and Executive Director of the The Two Frontiers Project Apply to… 📎 Supply Chain Engineer, Cellular Origins 📎 VP of Commercial Implementation, Culmination Bio 📎 VP, Next Generation Therapeutics, Asklepios BioPharmaceutical, Inc. (AskBio) Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #17 out now: https://lnkd.in/exJX9JrB #biotechdodo #biotech #pharma #digitalhealth #healthtech

🦤 Looks like it’s a season of change and fresh thoughts! Sir Gregory Winter joins Constructive Bio, vertical farming gets a smart energy-saving boost, Pfizer makes the tough call to withdraw Oxbryta, the slow-and-steady approach to AI in cell therapies and Bristol Myers Squibb’s long-awaited schizophrenia treatment – the first new one in decades👇 ❄️ Winter of great content: Sir Greg joins board as Constructive Bio takes funding haul to $75m (Tony Quested) 🐌 Cell therapy developers should build slowly with artificial intelligence (Gareth Macdonald) ❌ Pfizer pulls sickle cell med Oxbryta off market after deaths (Phil Taylor) 🌾 New indoor vertical farming research could help future-proof food demand for a changing planet (Frontiers in Science) 🥇FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades (Annika Kim Constantino) Tune into… 🎧 Should scientists endorse political candidates? With Cameron English and Dr. Liza Dunn 🎧 Uncertainties in gene drive technology for agricultural pest control in the U.S. with Nourou Barry, PhD Anthropologist and Postdoctoral Scholar at NC State University Apply to… 📎 Senior Technical Recruiter, WhiteLab Genomics 📎 Project Engineer - Global Robotics, Eli Lilly and Company 📎 Chief Scientific Adviser, FCDO Services Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #16 out now: https://lnkd.in/exvW8i5v #biotechdodo #biotech #pharma #digitalhealth #healthtechch

🦤 From insulin pricing spats and autoimmune treatment showdowns, to stem cell breakthroughs, superbug survival strategies, and a bold battle over cancer diagnostics – competition is fierce in biotech right now. This week’s biotech news👇 ⚖️ FTC sues major pharmacy benefit managers over price of insulin (Luke Halpern) 🩸 AstraZeneca wins rare autoimmune indication for Asthma biologic Fasenra (Tristan Cesar Mañalac) 💰 Stem cell startup spun out of George Church’s lab raises $75M (Ryan Cross) 🦠 Superbugs ‘could kill 39m people by 2050’ amid rising drug resistance (Kat Lay) 🍿 The Battle Brewing Over Blood Tests for Cancer (David Wainer) Tune into… 🎧 Fear, facts and frustration: Why scientists need to speak up, with Karl Schmieder, MS MFA and Erum Azeez Khan 🎧 Breaking biotech barriers: RNA’s next frontier with Rahul Chaturvedi 🎧 Estonia’s biobank: Is this the first large-scale personalised medicine initiative? With Jim Cornall Apply to… 📎 R&D Imaging Engineer, IXICO 📎 Organoid Scientist, a:head bio AG 📎 US Market Access Pipeline Director, AbbVie Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #15 out now: https://lnkd.in/eHbBiFgR #biotechdodo #biotech #pharma #digitalhealth #healthtech

Good morning fine readers. This week, we bring you tales of genetic twists, turns and turmoil…🦤 This week’s biotech news👇 🧬 Turmoil strikes 23andMe as board members resign in dispute with founder (Daniel Gilbert) 🧑💻 Google Cloud And Ginkgo Bioworks Partner To Launch New Protein LLM and API (Sai Balasubramanian, M.D., J.D.) 🤖 Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform (Fraiser Kansteiner) 💉 Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver (Nick Paul Taylor) 📈 Ascendis trial data piles pressure on BioMarin (Ned Pagliarulo) 🧬 How a struggling biotech company became a university ‘spin-in’ Tune into…  🎧 Navigating challenges and transitioning into leadership: with @ Jon Chee and Derek Hennecke, Board Member at Kincell Bio 🎧 Swimming in the new oil: with Daniel Levine and Lincoln Nadauld, President and CEO at Culmination Bio 🎧 Engineering the future of drug discovery: with Murat Tunaboylu, CEO and Co-Founder at Antiverse Apply to…  📎 Genomics Bioinformatician, Basecamp Research 📎 Associate Director for Scientific Programs, InVitro Cell Research, LLC 📎 Biotechnology Research Associate, Oppenheimer & Co. Inc. RSVP… 📆 23.09 | Healthtech Talks | London, UK 📆 26.09 | Endpoints 11 | Boston, US 📆 26.09 | Webinar: Empowering Patients to Overcome Challenges in Orphan Drug Development 📆 15.10 | European Cell & Gene Therapy Summit 2024 | London, UK Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #14 out now: https://lnkd.in/eqdc7tpe #biotechdodo #biotech #pharma #digitalhealth #healthtech

Good morning from beyond the horizon 🦤 It’s all quantum leaps and heart-in-a-jars this week – and no, we’re not talking about yet another nostalgic sci-fi reboot. This week’s biotech news👇 🦘 New initiative aims to position Australia at the forefront of quantum biotech (The University of Queensland) 🦠 Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal (Max Gelman) 🧠 Astrocytes reprogrammed into brain stem cells through epigenetic modifications (Genetic Engineering & Biotechnology News) 🫀 Biotech firm Medera set to go public in $623M SPAC deal (Bloomberg News) 🧵 Ingenza Partners with Cellugy to Boost Biofabricated Cellulose Production (Mrudula Kulkarni) Tune into… 🎧 Leveraging wastewater and AI to predict population health threats: with Dr. Andrée Bates and Mariana Matus, PhD from Biobot Analytics 🎧 Raising the bar for sickle cell disease patients: with Luke Timmerman, Ted W. Love, MD from Biotechnology Innovation Organization, and Dr. Alan Anderson from Sickle Forward 🎧 Cracking the biological code of ageing: with Patrick Short Martin Borch Jensen from Gordian Biotechnology and Norn Group Apply to… 📎 Principal Computational Biologist, Ochre Bio 📎 Technical Project Manager, Isomorphic Labs 📎  Biotech Account Manager, Thermo Fisher Scientific Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #13 out now: https://lnkd.in/ex67AdzV #biotechdodo #biotech #pharma #digitalhealth #healthtech

Twelve weeks ago at SomX we launched our brand new newsletter Biotech Dodo - here are a few things I’ve learned about newsletters. I didn't actually expect it to be such a hit so quickly, but hundreds of you have subscribed (appreciate you 🙏🏼) so I thought I'd share a behind the scenes on how we went about planning and executing on a new format that might be helpful if you're planning a newsletter. 1. We wanted to add value to the community by splitting the biotech stories out of Healthtech Pigeon and creating a brand for the biotech space. 2. We knew the Healthtech Pigeon format worked, which, broadly, is to curate the best news, podcasts and opportunities and add an analyses with humour to make it insightful and fun to read. 3. We didn't want it to be exactly the same and biotech has an additional challenge - lots of very hard science. So the question was: how do we add the most value to our readers? 4. We experimented with various formats, but felt that biotech news articles can sometimes be difficult to follow, require a lot of prior knowledge and reading article after article can be heavy and tough to do, so summarising the science was a definite value-add. 5. But, just summarising didn't add enough value, and the most common feeling after reading news articles was 'so what,' which is why for each article, we've added 'our take' which gives our reflection and opinion on that story, which helps readers understand where the current news fits into what's going on overall in that area. 6. We ran a pilot and knew at that point we had our format and thanks to those people that have messaged to say you're enjoying it. 7. For the name - my Dad's from Mauritius and Dodo's are (were ☹️) hilarious so that wrote itself. And the cartoon bird thing has given us all a bit of light entertainment over the years so why not! With newsletters I think it's really important to get out of your own head with your own wants and wishes. For the quickest growth, it's about figuring out the audience you want to help and actually finding the best way to help them. Yes, have a vision for broadly what you want to do, who you want to do it for and how you want to do it, but work out and iterate the detail with a serious focus on the value add. Avoid recycling your company news and messages and expecting people to subscribe. Make the newsletter as practically useful as possible. To subscribe to our new one - head to Biotech Dodo & hit "Visit Website" PS - dodo emoji is ideal 🦤 #biotech #healthtech #newsletter #pharma

Good morning my eagle-eyed readers, This week’s biotech news brings funding for the UK’s life sciences sector, RNA-driven cancer therapies, a $300 billion bioeconomy, some eye-watering scrutiny from the FDA and a new tool to decode some pesky folding proteins👇 🇬🇧 UK government partners with pharma on new £400M life science infusion (Max Bayer) 🧬 Bayer partners with RNA drugmaker to develop new cancer therapies  (Delilah Alvarado) 👀 EyePoint dinged with FDA warning letter over manufacturing (Fraiser Kansteiner) 🇮🇳 Policy push for India’s bioeconomy (Sahana Ghosh & Subhra Priyadarshini) 🤖 Researchers present AI-guided protein design tool (Thomas Gabrielczyk) Tune into… 🎧 A tough ending, new beginnings, and China – US biopharma relations: with Heather McKenzie, Jennifer "Jef" Akst , and Greg Slabodkin 🎧 New German biotech spins out to develop radiotherapeutics: Jim Cornall chats with Andreas Eckert from Pentixapharm AG 🎧 Jerry McLaughlin, CEO Life Biosciences: Max Brennan, MSc interviews Jerry McLaughlin from Life Biosciences Apply to… 📎 Airlock Coordinator, Genomics England 📎 Intern Biomedical Data Scientist, Orakl Oncology 📎 Head of Manufacturin: Cell Therapy, Takeda Keep an eye on all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #12 out now: https://lnkd.in/eNKMF65z #biotechdodo #biotech #pharma #digitalhealth #healthtech